Evidence map›Paper›PMID 42523804›Full record

ArticleInternational journal of ophthalmology2026

The trends of retinoblastoma research in the past decade.

Yu-Hang Yang, Wen-Da Zhou, Han-Qing Zhao, Rui-Heng Zhang, Li Dong, Lei Shao, Wen-Bin Wei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yu-Hang YangBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Key Laboratory of Intelligent Diagnosis, Treatment and Prevention of Blinding Eye Diseases, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Wen-Da ZhouBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Key Laboratory of Intelligent Diagnosis, Treatment and Prevention of Blinding Eye Diseases, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Han-Qing ZhaoBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Key Laboratory of Intelligent Diagnosis, Treatment and Prevention of Blinding Eye Diseases, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Rui-Heng ZhangBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Key Laboratory of Intelligent Diagnosis, Treatment and Prevention of Blinding Eye Diseases, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Li DongBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Key Laboratory of Intelligent Diagnosis, Treatment and Prevention of Blinding Eye Diseases, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Lei ShaoBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Key Laboratory of Intelligent Diagnosis, Treatment and Prevention of Blinding Eye Diseases, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Wen-Bin WeiBeijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Key Laboratory of Intelligent Diagnosis, Treatment and Prevention of Blinding Eye Diseases, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo conduct a bibliometric analysis of retinoblastoma (RB) research to delineate global research trends, identify key research contributors, and highlight emerging research directions in this field.

methodsPublications from 2015 to 2024 were collected from the Web of Science Core Collection. Data on publication volume, citations, H-indexes, and collaborative networks were analyzed using CiteSpace.

resultsIn total, 1719 publications were included. Annual publication outputs on RB research exhibited an overall upward trend. The United States dominated global RB research with 500 publications (29.09%), 8978 citations and an H-index of 43, followed by China (468 articles, 27.23%) and India. Switzerland and Spain yielded the highest average citation per article, at 29.00 and 27.72, respectively. Institution-wise, Thomas Jefferson University (76 publications) and Memorial Sloan Kettering Cancer Center (70 publications) ranked top in publication quantity.

conclusionThis study performed the first decade-long CiteSpace-based bibliometric analysis of RB. Substantial disparities in publication productivity and clinical practice exist across nations and institutions. Low- and middle-income countries (LMICs) remain burdened by diagnostic and therapeutic limitations for RB, highlighting the necessity of strengthened international collaboration. Future research priorities encompass overcoming chemotherapy resistance, optimizing intra-arterial chemotherapy (IAC) regimens, and translating molecular discoveries into accessible therapies

Indexed as

bibliometricsCiteSpaceretinoblastoma

Identifiers

PMID42523804
PMCPMC13407710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.